Tonix Pharmaceuticals Holding Corp. (TNXP) 8-K Current Report: March 10, 2026
Filed: March 10, 2026
Health Care
Pharmaceutical PreparationsTonix Pharmaceuticals Holding Corp. (TNXP) 8-K current report filed with SEC EDGAR on March 10, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 7.01: Regulation FD Disclosure
- Item 8.01: Other Events
Tonix Pharmaceuticals Holding Corp. 8-K Mar 10, 2026 Event Analysis
Item 7.01 · Regulation FD Disclosure
- • Legal boilerplate only: Exhibit/information filed under Item 7.01 explicitly not subject to Section 18 liability or incorporated by reference
- • No material business, financial, or operational information disclosed in the provided text — full substance likely in an accompanying exhibit
Item 8.01 · Other Events
- • TONMYA met primary endpoint in RESILIENT Phase 3 trial (457 adults, 14 weeks) with high significance (p<0.001); pain relief observed as early as Day 2
- • Least-squares mean treatment difference of -0.65 on pain NRS scale; all key secondary endpoints also statistically significant
- • Pooled analysis (959 participants, RELIEF + RESILIENT trials): NNT of 7 for ≥30% pain reduction vs. placebo at Week 14
- • NNH for adverse-event discontinuation was 26; LHH ratio of 3.7 — nearly 4x greater likelihood of benefit than harm
- • Data presented at ICCF strengthens TONMYA's commercial and regulatory positioning as an approved fibromyalgia therapy
Other Tonix Pharmaceuticals Holding Corp. 8-K Filings
Get deeper insights on Tonix Pharmaceuticals Holding Corp.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.